JP2020523348A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523348A5
JP2020523348A5 JP2019568372A JP2019568372A JP2020523348A5 JP 2020523348 A5 JP2020523348 A5 JP 2020523348A5 JP 2019568372 A JP2019568372 A JP 2019568372A JP 2019568372 A JP2019568372 A JP 2019568372A JP 2020523348 A5 JP2020523348 A5 JP 2020523348A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
cancer
salt according
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019568372A
Other languages
English (en)
Japanese (ja)
Other versions
JP6979595B2 (ja
JP2020523348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037221 external-priority patent/WO2018231910A1/en
Publication of JP2020523348A publication Critical patent/JP2020523348A/ja
Publication of JP2020523348A5 publication Critical patent/JP2020523348A5/ja
Application granted granted Critical
Publication of JP6979595B2 publication Critical patent/JP6979595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019568372A 2017-06-13 2018-06-13 プロテインキナーゼ阻害剤としてのアミノチアゾール化合物 Active JP6979595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762518855P 2017-06-13 2017-06-13
US62/518,855 2017-06-13
PCT/US2018/037221 WO2018231910A1 (en) 2017-06-13 2018-06-13 Aminothiazole compounds as protein kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2020523348A JP2020523348A (ja) 2020-08-06
JP2020523348A5 true JP2020523348A5 (enExample) 2021-07-26
JP6979595B2 JP6979595B2 (ja) 2021-12-15

Family

ID=64562741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019568372A Active JP6979595B2 (ja) 2017-06-13 2018-06-13 プロテインキナーゼ阻害剤としてのアミノチアゾール化合物

Country Status (13)

Country Link
US (1) US10300061B2 (enExample)
EP (1) EP3638237B1 (enExample)
JP (1) JP6979595B2 (enExample)
KR (1) KR102372288B1 (enExample)
CN (1) CN110831596B (enExample)
AU (1) AU2018284249B2 (enExample)
CA (1) CA3064081C (enExample)
ES (1) ES2949616T3 (enExample)
MX (1) MX393992B (enExample)
MY (1) MY201291A (enExample)
TW (1) TWI667236B (enExample)
WO (1) WO2018231910A1 (enExample)
ZA (1) ZA202000107B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102797697B1 (ko) 2018-05-25 2025-04-22 에이2에이 파마수티칼스, 잉크. 신종 항암제 후보로서, 매우 강력한 tacc3 억제제
KR20220103744A (ko) * 2019-11-14 2022-07-22 에이2에이 파마수티칼스, 잉크. 항암제로서 tacc3을 표적으로 하는 이속사졸 유도체
CN116348116A (zh) * 2020-03-06 2023-06-27 台湾卫生研究院 嘧啶化合物及其医药用途
US11299489B1 (en) 2020-11-19 2022-04-12 National Health Research Institutes Thiazole compounds as protein kinase inhibitors
WO2022221194A1 (en) * 2021-04-12 2022-10-20 A2A Pharmaceuticals, Inc. Compositions and methods for treating cancer
EP4499625A4 (en) 2022-03-24 2026-03-18 A2A Pharmaceuticals Inc CANCER COMPOSITIONS AND TREATMENT METHODS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003285007A1 (en) * 2002-10-30 2004-06-07 Merck & Co., Inc. Kinase inhibitors
EP2361624A1 (en) * 2005-04-04 2011-08-31 AB Science Oxazole derivatives and their use as tyrosine kinase inhibitors
JP2008543754A (ja) * 2005-06-09 2008-12-04 メルク エンド カムパニー インコーポレーテッド チェックポイントキナーゼの阻害剤
GB0610909D0 (en) 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
CA2662580C (en) * 2006-09-11 2013-05-21 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
TW200906825A (en) 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
US9255072B2 (en) * 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
AU2012288900B2 (en) * 2011-07-27 2016-10-06 Ab Science Selective protein kinase inhibitors
WO2013143466A1 (zh) * 2012-03-27 2013-10-03 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
CN106279143A (zh) * 2015-05-11 2017-01-04 天津国际生物医药联合研究院 噻唑杂环类化合物及其制备方法和应用
WO2018106643A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases

Similar Documents

Publication Publication Date Title
JP2019511564A5 (enExample)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
ES2779152T3 (es) Derivados de (2-(5-isoindolin-2-il)pirimidin-4-il)-amina como inhibidores de Rho-quinasa para tratar enfermedades autoinmunes
US9725444B2 (en) Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
TWI594986B (zh) Antineoplastic agent effect enhancer
WO2020130125A1 (ja) 抗体-薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
ES2576497T3 (es) Compuesto de piperidina novedoso o sal del mismo
JP2019535746A5 (enExample)
JP2020503299A5 (enExample)
CA2519898A1 (en) Oral administration of cyclic protein tyrosine kinase inhibitors
CN109568312A (zh) 用于治疗癌症的化合物
JP2015518899A5 (enExample)
CA2520586A1 (en) Novel ido inhibitors and methods of use
RU2016130932A (ru) Производные хинолона как ингибиторы рецептора фактора роста фибробластов
WO2018147275A1 (ja) 腫瘍治療用医薬組成物
JP2020536971A5 (enExample)
RU2017139515A (ru) Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там
JP2005508953A5 (enExample)
JP6883913B2 (ja) ヒストンデメチラーゼ阻害剤
RU2016137356A (ru) Соединение нафтиламида, способ его получения и применение
JP2020534300A5 (enExample)
RU2010106241A (ru) Применение имидазохинолинов для лечения заболеваний, зависимых от egfr, или заболеваний с приобретенной резистентностью к агентам, которые связываются с членами семейства egfr
CN117865886A (zh) 一种n-(喹啉-8-基)喹啉-8-磺酰胺类化合物及其应用
JP2023542065A5 (enExample)
CA3130471A1 (en) Pan-raf kinase inhibitor and use thereof